发现了针对VEGFR2,EphB4,FGFR-1和TIE-2的新型多血管原体:基于受体的药模型,虚拟查和分子建模研究
Jeevan Patra1, Amit K Keshari1, Richie R Bhandare2,3
1Department of Pharmaceutical Chemistry, Amity Institute of Pharmacy, Amity University Uttar Pradesh, Lucknow Campus, Lucknow 226028, Uttar Pradesh, India.
ACS omega
|April 21, 2025
概括
这项研究确定了针对关键蛋白质 (VEGFR2,EphB4,FGFR-1,TIE-2) 的新型天然化合物,以抑制癌症血管生成和进展. 三种化合物显示出开发新抗癌疗法的前景.
科学领域:
- 药物的发现和开发.
- 计算化学是一种计算化学.
- 分子生物学分子生物学
背景情况:
- 血管新生,新血管的形成,对于癌细胞的生长和进展至关重要.
- 针对VEGFR2,EphB4,FGFR-1和TIE-2等关键蛋白质提供了一种抑制瘤发展的策略.
研究的目的:
- 通过向VEGFR2,EphB4,FGFR-1和TIE-2来识别可以抑制血管生成的多式自然化合物.
- 探索天然产品作为新型抗癌药物候选药物的来源的潜力.
主要方法:
- 开发并验证了基于VEGFR2,EphB4,FGFR-1和TIE-2的受体药模型.
- 通过使用经过验证的药模型选的天然产品数据库 (超自然3.0,子,莲花).
- 使用绝对终点方法和密度函数理论 (DFT) 进行稳定性分析,评估结合亲和度.
主要成果:
- 确定了17种自然化合物,这些化合物与药理学模型准确对齐.
- 根据结合能量,相互作用,分子动力学和药用动力学概况,选择了三个有前途的化合物 (CNP0003920,CNP0243075,CNP0211397).
- DFT证实了已识别的化合物与蛋白质复合体结合的稳定性.
结论:
- 已识别的天然化合物显示出开发针对VEGFR2,EphB4,FGFR-1和TIE-2的多式疗法药物的起点.
- 这些发现为新的抗癌治疗策略提供了有希望的途径,重点是抑制血管生成.
更多相关视频
07:32Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
Published on: September 30, 2019
7.6K
08:04In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
Published on: May 11, 2021
2.7K
相关概念视频
01:24Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
01:10Mechanism of Angiogenesis
5.0K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.0K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K